U.S. Startup Funding Rounds Top $953 Million for Nov. 14-20
U.S. startups secured $953 million across four confirmed funding rounds from November 14 to 20, 2026, led by Science's $400 million Series D. The week's deals were dominated by health and neuroscience companies.

U.S. startup funding rounds from November 14 to 20, 2026, totaled $953 million across four confirmed deals. The weekly report highlights the largest venture capital injections into American companies, with brain-computer interface firm Science leading the pack.
Top funding rounds
The largest deal of the period was a $400 million Series D round for Science. The Alameda-based neurotech startup, founded in 2021, has now raised over $900 million in total. This single round accounted for roughly 42 percent of the week's confirmed funding. Science is developing a machine learning-powered brain implant called PRIMA, which targets vision loss.
In second place, Model ML raised $250 million in a Series B round. The financing was led by General Atlantic and QED Investors and valued the company at $1.5 billion. Its customers are in the finance sector.
| Company | Round Size | Round Type | Lead Investor(s) |
|---|---|---|---|
| Science | $400 million | Series D | Not specified |
| Model ML | $250 million | Series B | General Atlantic, QED Investors |
| Galvanize Therapeutics | $130 million | Series D | HealthQuest Capital |
| Marrow Therapeutics | $173 million | Series A & B Combined | Not specified |
Other notable deals
Galvanize Therapeutics secured $130 million in a Series D round led by HealthQuest Capital. The company operates in the medtech and oncology space.
Marrow Therapeutics announced a combined $173 million in Series A and Series B funding at its launch. The breakdown shows a $53 million Series A and a $120 million Series B.
Health and neuroscience deals collectively made up 74 percent of the $953 million in confirmed funding for the week. This concentration reflects, in part, a response to the long development timelines typical of medical device and drug programs.
Additional funding activity
Several other companies disclosed large funding rounds, though these were not among the four fully confirmed deals. General Flash raised $128 million across seed and Series A rounds. Ramon.Space secured $124 million in Series B funding. Noeri attracted $110 million in initial funding. Seawolf Therapeutics has raised $100 million to date. BrightAI secured $97 million in new capital. Vincue closed on $93 million in growth funding.
Globally, Isomorphic Labs secured a massive $5 billion in Series C financing. The report also noted that tech stocks experienced significant volatility recently, while Anthropic headlined tech startup exits with its massive initial public offering.
Industry data indicates a complex picture for technology adoption. While 80 percent of enterprise buyers reported productivity gains from new tools, only 37 percent saw those gains translate into profit.
Weekly funding roundups inherently reward deal size, which can distort perceptions of the broader market. The timing of announcements also adds noise, as rounds may have closed days or weeks before the press releases are issued. The report's format continues to highlight size as a key metric despite this potential for distortion.





